Market Currents
Zipharm Oncology (ZIOP) +5.7% after providing positive Phase 3 trial data for its Picasso 3...
-
Monday, April 2, 2012, 9:27 AM ETZipharm Oncology (ZIOP) +5.7% after providing positive Phase 3 trial data for its Picasso 3 sarcoma drug. The results correlate with positive data reported in February. (PR)
Other date
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles
